Trials / Completed
CompletedNCT00105092
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzastaurin HCL |
Timeline
- Start date
- 2005-03-01
- Completion
- 2007-02-01
- First posted
- 2005-03-07
- Last updated
- 2007-05-01
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105092. Inclusion in this directory is not an endorsement.